Kyung-Min Lee

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 14

Top Venues

Nature communications

Biomedicines

Animal cells and systems

Research square

Vanderbilt University Medical Center

Hanyang University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Vanderbilt University Medical Center Nov 01 2014 - Nov 30 2017

United States

Research Fellow :: Hematology/Oncology

Education History

Hanyang University

South Korea

PHD :: Life Science

Hanyang University

South Korea

BSC :: Life Science

Publications

Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph J Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Nature communications 15 (1) (2024)
Tae-Won Lee, Hee-Joo Choi, Kyung-Min Lee, Jeong-Yeon Lee
Special Issue: Resistance to Targeted Therapies in Human Cancer. Biomedicines 11 (2) (2023)
Tae-Won Lee, Hee-Joo Choi, Kyung-Min Lee, Jeong-Yeon Lee
Special Issue: Resistance to Targeted Therapies in Human Cancer. Biomedicines 11 (2) (2023)
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-Min Lee, Xuemei Luo, Joseph Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram S Mani, David W Cescon, Lin Xu, Yang Xie, Joshua T Mendell, Ariella B Hanker, Carlos L Arteaga
Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research square (2023)
Tae-Won Lee, Hee-Joo Choi, Kyung-Min Lee, Jeong-Yeon Lee
Special Issue: Resistance to Targeted Therapies in Human Cancer. Biomedicines 11 (2) (2023)
Hyungjoo Kim, Je-Min Choi, Kyung-Min Lee
Immune Checkpoint Blockades in Triple-Negative Breast Cancer: Current State and Molecular Mechanisms of Resistance. Biomedicines 10 (5) (2022)
Kyung-Min Lee, Chang-Ching Lin, Alberto Servetto, Joonbeom Bae, Vishal Kandagatla, Dan Ye, Gun Min Kim, Dhivya R Sudhan, Saurabh Mendiratta, Paula I Gonzalez Ericsson, Justin M Balko, Jeon Lee, Spencer Barnes, Venkat S Malladi, Siamak Tabrizi, Sangeetha M Reddy, Seoyun Yum, Ching-Wei Chang, Katherine E Hutchinson, Susan E Yost, Yuan Yuan, Zhijian J Chen, Yang-Xin Fu, Ariella B Hanker, Carlos L Arteaga
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. Cancer immunology research 10 (7) (2022)
Tae Won Lee, Kyung-Min Lee
ECM1 is associated with endocrine resistance in ER + breast cancers. Animal cells and systems 26 (3) (2022)
Seogho Son, Seung-Ah Yoo, KeeSoo Nam, Sunhwa Oh, Kyung-Min Lee, Jae Youn Yi, Incheol Shin
Brain type of creatine kinase induces doxorubicin resistance via TGF-β signaling in MDA-MB-231 breast cancer cells. Animal cells and systems 26 (5) (2022)
Kyung-Min Lee, Angel L Guerrero-Zotano, Alberto Servetto, Dhivya R Sudhan, Chang-Ching Lin, Luigi Formisano, Valerie M Jansen, Paula I Gonzalez Ericsson, Melinda E Sanders, Thomas P Stricker, Ganesh Raj, Kevin M Dean, Reto Paul Fiolka, Lewis C Cantley, Ariella B Hanker, Carlos L Arteaga
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. Nature communications 11 (1) (2020)

Kyung-Min Lee.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Kyung-Min Lee